American Century Companies Inc. Boosts Stock Holdings in Protagonist Therapeutics, Inc. $PTGX

American Century Companies Inc. grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 18.7% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 813,995 shares of the company’s stock after buying an additional 128,171 shares during the quarter. American Century Companies Inc.’s holdings in Protagonist Therapeutics were worth $44,990,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. FNY Investment Advisers LLC purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter worth $27,000. Bessemer Group Inc. grew its position in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after acquiring an additional 318 shares during the period. CWM LLC increased its stake in Protagonist Therapeutics by 201.5% during the second quarter. CWM LLC now owns 609 shares of the company’s stock worth $34,000 after acquiring an additional 407 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Protagonist Therapeutics by 141.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,211 shares of the company’s stock worth $59,000 after purchasing an additional 710 shares during the period. Finally, Brooklyn Investment Group purchased a new position in shares of Protagonist Therapeutics in the 1st quarter worth about $68,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $89.98 on Friday. The company’s fifty day moving average price is $76.65 and its two-hundred day moving average price is $61.81. The firm has a market capitalization of $5.63 billion, a P/E ratio of 145.12 and a beta of 2.22. Protagonist Therapeutics, Inc. has a 12 month low of $33.70 and a 12 month high of $93.25.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.03). Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. The business had revenue of $4.71 million for the quarter, compared to analyst estimates of $5.41 million. On average, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PTGX. Johnson Rice set a $112.00 target price on Protagonist Therapeutics in a report on Monday, October 13th. Truist Financial lifted their price target on shares of Protagonist Therapeutics from $76.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. JMP Securities increased their price objective on shares of Protagonist Therapeutics from $67.00 to $69.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 7th. BTIG Research reissued a “buy” rating and issued a $82.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Finally, Leerink Partnrs upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a report on Friday, September 12th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $82.23.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $81.62, for a total value of $979,440.00. Following the transaction, the director directly owned 5,130 shares of the company’s stock, valued at $418,710.60. This represents a 70.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.90% of the stock is owned by corporate insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.